Pages that link to "Q62089079"

The following pages link to Florence Raynaud (Q62089079):

Displaying 50 items.

• Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease (Q24310764) (← links)
• Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer (Q24646000) (← links)
• A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy (Q24646209) (← links)
• Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues (Q27644429) (← links)
• 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors (Q27644640) (← links)
• Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate (Q27662513) (← links)
• Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia (Q27674324) (← links)
• Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing (Q27675773) (← links)
• The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design (Q27680079) (← links)
• Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells (Q27680538) (← links)
• Structure-Based Design of Orally Bioavailable 1 H -Pyrrolo[3,2- c ]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1) (Q27680652) (← links)
• Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach (Q27704528) (← links)
• Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737) (Q27704842) (← links)
• First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors (Q27853088) (← links)
• A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors (Q28304273) (← links)
• Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors (Q28817295) (← links)
• Assessing histone demethylase inhibitors in cells: lessons learned. (Q30361704) (← links)
• Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. (Q33276971) (← links)
• Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer (Q33499775) (← links)
• Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy (Q33639719) (← links)
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (Q33770362) (← links)
• Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. (Q33811946) (← links)
• The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. (Q33959529) (← links)
• Effect of sleep deprivation on the human metabolome (Q33972140) (← links)
• Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. (Q34798892) (← links)
• The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. (Q34981765) (← links)
• Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. (Q35177853) (← links)
• Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. (Q35560868) (← links)
• A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy (Q35582260) (← links)
• Drugging the PI3 kinome: from chemical tools to drugs in the clinic. (Q35622141) (← links)
• Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. (Q35974177) (← links)
• Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. (Q36116129) (← links)
• The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma (Q36160258) (← links)
• CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. (Q36328196) (← links)
• A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. (Q36367502) (← links)
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns (Q36469916) (← links)
• A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days (Q36610517) (← links)
• A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. (Q36615465) (← links)
• A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. (Q36673831) (← links)
• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma (Q36771796) (← links)
• Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 (Q37094837) (← links)
• Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. (Q37281508) (← links)
• Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation (Q37660266) (← links)
• Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs (Q37798159) (← links)
• Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors (Q37886009) (← links)
• 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent (Q38841925) (← links)
• Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. (Q39037415) (← links)
• Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution (Q39400725) (← links)
• Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. (Q39581478) (← links)
• Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor (Q39631279) (← links)